SG171674A1 - Methods of treating cancer by administering human il-18 combinations - Google Patents

Methods of treating cancer by administering human il-18 combinations

Info

Publication number
SG171674A1
SG171674A1 SG201103315-6A SG2011033156A SG171674A1 SG 171674 A1 SG171674 A1 SG 171674A1 SG 2011033156 A SG2011033156 A SG 2011033156A SG 171674 A1 SG171674 A1 SG 171674A1
Authority
SG
Singapore
Prior art keywords
combinations
human
methods
treating cancer
administering human
Prior art date
Application number
SG201103315-6A
Other languages
English (en)
Inventor
Zdenka Haskova
Zdenka Ludmila Jonak
Stephen H Trulli
Margaret N Whitacre
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG171674(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of SG171674A1 publication Critical patent/SG171674A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
SG201103315-6A 2007-03-23 2008-03-20 Methods of treating cancer by administering human il-18 combinations SG171674A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
SG171674A1 true SG171674A1 (en) 2011-06-29

Family

ID=39788932

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201103315-6A SG171674A1 (en) 2007-03-23 2008-03-20 Methods of treating cancer by administering human il-18 combinations

Country Status (21)

Country Link
US (4) US20090035258A1 (ja)
EP (3) EP2129398A4 (ja)
JP (2) JP2010522200A (ja)
KR (2) KR20100015798A (ja)
CN (1) CN101678102A (ja)
AR (2) AR065803A1 (ja)
AU (2) AU2008231025A1 (ja)
BR (2) BRPI0809079A2 (ja)
CA (2) CA2681827A1 (ja)
CL (2) CL2008000818A1 (ja)
CR (2) CR10996A (ja)
DO (2) DOP2009000208A (ja)
EA (2) EA200970885A1 (ja)
IL (2) IL200525A0 (ja)
MA (2) MA31265B1 (ja)
MX (2) MX2009010269A (ja)
NZ (1) NZ579179A (ja)
PE (2) PE20090190A1 (ja)
SG (1) SG171674A1 (ja)
TW (2) TW200906436A (ja)
WO (2) WO2008118733A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800450A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
ES2764110T3 (es) 2014-04-25 2020-06-02 Pf Medicament Conjugado anticuerpo-fármaco y su utilización para el tratamiento del cáncer
ES2727103T3 (es) 2014-04-25 2019-10-14 Pf Medicament Conjugado anticuerpo-fármaco para IGF-1R y su utilización para el tratamiento del cáncer
NZ729395A (en) 2014-08-07 2018-04-27 Hyogo College Medicine Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
US10618970B2 (en) * 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2022115946A1 (en) * 2020-12-02 2022-06-09 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0692536B1 (en) 1994-07-14 2000-11-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo IFN-Y production inducing protein and monoclonal antibody of the same
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
HUP0501002A3 (en) * 2000-06-15 2010-01-28 Smithkline Beecham Corp Method for preparing a physiologically active il-18 polypeptide
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
JP2005526044A (ja) * 2002-02-21 2005-09-02 デューク ユニバーシティ 抗ｃｄ２２抗体を使用した治療方法
SI1545587T1 (sl) * 2002-09-16 2011-06-30 Agennix Inc Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede
CA2501757C (en) * 2002-10-08 2012-04-24 Immunomedics, Inc. Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
NZ581541A (en) * 2002-10-17 2011-07-29 Genmab As Human monoclonal antibodies against CD20
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP1613274B1 (en) * 2003-04-15 2010-03-03 GlaxoSmithKline LLC Human il-18 substitution mutants and their conjugates
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
CA2534639C (en) * 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
RU2412199C2 (ru) * 2005-04-18 2011-02-20 Ново Нордиск А/С Варианты ил-21
ES2530265T3 (es) * 2005-07-21 2015-02-27 Genmab A/S Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
EP2368566A1 (en) * 2006-07-13 2011-09-28 ZymoGenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
JP2010503680A (ja) * 2006-09-14 2010-02-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ヒトｉｌ−１８による調節ｔ細胞のモジュレーション
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento

Also Published As

Publication number Publication date
BRPI0809079A2 (pt) 2019-03-06
AR065803A1 (es) 2009-07-01
CN101678102A (zh) 2010-03-24
DOP2009000220A (es) 2009-10-31
CA2681851A1 (en) 2008-10-02
CR11075A (es) 2010-03-22
AU2008231114A1 (en) 2008-10-02
BRPI0808943A2 (pt) 2014-08-26
NZ579179A (en) 2011-12-22
EP2129398A4 (en) 2010-04-21
CL2008000842A1 (es) 2008-10-17
EA200970884A1 (ru) 2010-04-30
WO2008118736A1 (en) 2008-10-02
KR20100014530A (ko) 2010-02-10
WO2008118733A3 (en) 2008-11-27
IL200525A0 (en) 2010-04-29
EP2136841A2 (en) 2009-12-30
MA31265B1 (fr) 2010-03-01
EP2129398A1 (en) 2009-12-09
IL200863A0 (en) 2010-05-17
US20080274078A1 (en) 2008-11-06
TW200904469A (en) 2009-02-01
CA2681827A1 (en) 2008-10-02
EP2338514A1 (en) 2011-06-29
PE20090184A1 (es) 2009-03-22
MA31264B1 (fr) 2010-03-01
JP2010522200A (ja) 2010-07-01
KR20100015798A (ko) 2010-02-12
AR065818A1 (es) 2009-07-01
JP2010522239A (ja) 2010-07-01
WO2008118733A2 (en) 2008-10-02
EA200970885A1 (ru) 2010-02-26
AU2008231025A1 (en) 2008-10-02
US20100196310A1 (en) 2010-08-05
TW200906436A (en) 2009-02-16
CL2008000818A1 (es) 2008-09-26
CR10996A (es) 2009-11-12
MX2009010269A (es) 2009-10-12
PE20090190A1 (es) 2009-03-22
EP2136841A4 (en) 2010-07-07
US20100111945A1 (en) 2010-05-06
US20090035258A1 (en) 2009-02-05
MX2009010271A (es) 2009-10-12
DOP2009000208A (es) 2010-03-31

Similar Documents

Publication Publication Date Title
SG171674A1 (en) Methods of treating cancer by administering human il-18 combinations
PH12020550741A1 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
IL184617A0 (en) Dr5 antibodies and uses thereof
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
MX346924B (es) Compuestos de diarilhidantoina.
NZ596490A (en) Monoclonal antibodies that bind GT468 for the treatment of cancer
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX2010003815A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
MX2009003362A (es) Uso de interleucina-10 pegilada para tratamiento de cancer.
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
WO2006116592A3 (en) Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
MX340724B (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama.
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
MX2013010770A (es) Tratamiento de tumores solidos.
MX2008008185A (es) Antigenos de acido des-n-acetil-sialico, anticuerpos para los mismos, y metodos de uso en la terapia de cancer.
EP1708751A4 (en) METHOD OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGEN EXPOSED ON APOPTOTIC TUMOR CELLS
WO2006116451A3 (en) Antibodies with immune effector activity and that internalize in endosialin-positive cells
HK1076055A1 (en) Covalent conjugates between artemisinin-related endoperoxides and iron- carrying proteins and methods of use
WO2007149586A3 (en) Anti-c35 antibodies for treating cancer
WO2007075706A3 (en) Affinity optimized epha2 agonistic antibodies and methods of use thereof
WO2008070090A3 (en) Compositions and methods for diagnosing and treating cancer
WO2006116001A3 (en) Antibodies for the treatment of cancers
WO2007007152A3 (en) Anti-madcam antibodies to treat metastatic cancers and chloroma